ArticleNature immunology2024
Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control.
Abstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- PDCD1 gene polymorphisms linked with altered risk of female-specific hormone-dependent cancers: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Avoidance of cardiac toxicity during the application of immune checkpoint inhibitors: a safety systematic review combining network meta-analysis and pharmacovigilance study.Frontiers in immunology · 2026Pooled it
- Bispecific Antibody-Based Combination Therapies for B-Cell Lymphomas: Current Evidence and Future Perspectives.International journal of cancer · 2026Review
- RNF180 loss stabilizes BCAS4 to enhance PD-L1 expression and immune evasion in hepatocellular carcinoma.iScience · 2026Article
- ENO3-mediated glycolytic reprogramming participates in β-glucan-induced dendritic cells activation and anti-tumor responses.Cellular and molecular life sciences : CMLS · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- The electrical and chemical hypoxia-optimized (ECHO) bioreactor system enables scalable production of functionally preserved NK-exosomes validated in a syngeneic lung cancer model.Drug delivery and translational research · 2026Article
- T-Cell Exhaustion in the Tumor Microenvironment: Subcellular Dysfunction, Pan-Cancer Characteristics, and Therapeutic Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- GSH-Responsive Nanoparticles Enhance Hepatocellular Carcinoma Immunotherapy Through Synergistic Effects of Cuproptosis and PI3K Inhibitor Combination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Enhanced Anti-Lung Cancer Efficacy of Neo-BCV Combined with Cisplatin: Immune Activation and Tumor Microenvironment Remodeling.Vaccines · 2026Article
- Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma.Cell death & disease · 2026Article
- Multimodal radiomics for precision management of colorectal cancer.Discover oncology · 2026Review
- Spatial profiling uncovers multicellular dynamics in early relapse of hepatitis B virus-associated follicular lymphoma.Communications biology · 2026Article
- Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade.Science immunology · 2026Article
- Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Balancing Intrinsic and Extrinsic Factors in CD8Immune network · 2026Review
- Regulators of CD8Nature reviews. Immunology · 2026Review
- T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection.Frontiers in immunology · 2026Review
- Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.Signal transduction and targeted therapy · 2026Review
- Reversing T cell dysfunction in a novelFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Sarah A WeissDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4155-0346
Amy Y HuangDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6646-6503
Megan E FungDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Daniela MartinezBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Alex C Y ChenBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8358-5408
Thomas J LaSalleBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Brian C MillerDepartment of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Christopher D ScharerDepartment of Microbiology and Immunology, School of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7716-8504
Mudra HegdeBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Thao H NguyenDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2767-0528
Jared H RoweDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Jossef F OsbornDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Dillon G PattersonDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Natalia SifnugelDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
C Mei-An NolanDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8109-7339
Richard A DavidsonKrantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Marc A SchwartzBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3869-0150
Alexander P R BallyDepartment of Microbiology and Immunology, School of Medicine, Emory University, Atlanta, GA, USA.
Dennis K NeeldDepartment of Microbiology and Immunology, School of Medicine, Emory University, Atlanta, GA, USA.
Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5017-774X
Jeremy M BossDepartment of Microbiology and Immunology, School of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2432-1840
John G DoenchBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
W Nicholas HainingBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7871-3762
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. arlene_sharpe@hms.harvard.edu.ORCID http://orcid.org/0000-0002-9736-2109
Debattama R SenBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA. dsen@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-0947-8284
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Michela Locci · 2009 to 2026
$48.1MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI E. John Wherry · 2015 to 2026
$30.8MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MMedical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MMOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6MRegulation of PD-1 gene expressionR01AI113021 · NIAID · EMORY UNIVERSITY · PI BOSS, JEREMY M. · 2014 to 2024
$4.7MDissecting the enhancer logic governing immune cell fate decisionsDP2AI176139 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SEN, DEBATTAMA RAI · 2022 to 2025
$2.5MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MTargeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer MutationsK08CA248960 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILLER, BRIAN C · 2020 to 2024
$1.2MNCI NIH HHS K08 CA248960NCI NIH HHS T32 CA009172NCI NIH HHS T32 CA009216NCI NIH HHS T32 CA207021NIAID NIH HHS DP2 AI176139NIAID NIH HHS P01 AI056299NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI113021NIAID NIH HHS U19 AI082630NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32 CA921643U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01 AI052699
Abstract
PD-1 is a key negative regulator of CD8
Indexed as
CD8-Positive T-LymphocytesEpigenesis, GeneticMice, Inbred C57BLMice, KnockoutProgrammed Cell Death 1 ReceptorAnimalsEnhancer Elements, GeneticLymphocyte ActivationLymphocytic ChoriomeningitisMicePdcd1 protein, mouseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.